In prostate cancer, Ji et al. [110] discovered that PAFR activates the extracellular signal-regulated kinases (ERK) 1/2 pathway, leading to an increase in MMP-3 and a decrease in E-cadherin expression. The gene discussed is PTAFR; the disease is prostate carcinoma.